Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQSV4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the Department of Defense's medical supply chain, with the PPV-G GEN V contract positioning the company as one of multiple regional prime vendor contractors under the broader $30.3 billion acquisition strategy. The company's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with Stelara—an immunosuppressant and biologic agent—representing a key specialty pharmaceutical product in its distribution capabilities. The company's demonstrated performance across numerous delivery orders and unrestricted federal procurement demonstrates its ability to fulfill the diverse and specialized pharmaceutical requirements of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQSV4?
SPE2DR26FQSV4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FQSV4 worth?
The government has obligated $16,584 on SPE2DR26FQSV4.
Is contract SPE2DR26FQSV4 an order under another contract?
Yes. SPE2DR26FQSV4 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSV4 competed?
The extent of competition for SPE2DR26FQSV4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award